Stoke Therapeutics announced that its request for an expedited submission of a treatment for severe epilepsy has been postponed by the Food and Drug Administration (FDA). The decision follows a meeting in December 2023, where the FDA did not reject Stoke’s proposal to submit zorevunersen, a drug aimed at treating Dravet syndrome, before the completion of ongoing clinical trials.
In an interview, Stoke’s CEO Ian Smith revealed that while the FDA is not closing the door on the possibility of a faster filing, the agency has requested additional information from the company. This information will be critical for further discussions, which are expected to occur in the coming months.
Future Plans and Expectations
Stoke Therapeutics is currently engaged in a Phase 3 study of zorevunersen, which is projected to conclude in the middle of 2027. The company aims to make a decision regarding its regulatory strategy for the drug by mid-2024. The outcome of these discussions will significantly influence the drug’s availability for patients suffering from Dravet syndrome, a severe form of epilepsy that often leads to developmental delays and increased risk of sudden death.
The FDA’s request for more information indicates a cautious approach, reflecting the complexities involved in the approval process for new drugs. Zorevunersen has shown promise in preliminary studies, but regulatory bodies prioritize patient safety and thorough evaluation.
Stoke’s efforts to expedite the approval process underscore the urgency many families feel as they seek effective treatments for conditions like Dravet syndrome. The company continues to advocate for quicker access to therapies that could improve the lives of patients.
As Stoke Therapeutics moves forward, the collaboration with the FDA will be crucial. Stakeholders in the epilepsy community are closely monitoring developments, hoping for a positive resolution that would allow for earlier access to this potentially life-changing medication.
